Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK delivers sales and earnings growth in Q2 2019
Total EPS 19.5p, +>100% AER, +>100% CER; Adjusted EPS 30.5p +9% AER, +4% CER
Read more -
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive Chairman of the Board of Directors
Read more -
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
Week 96 data from the BRIGHTE study of first-in-class fostemsavir continue to show improvement in virologic suppression and immunologic response
Read more -
GSK ships 2019-20 seasonal influenza vaccines for US market
GSK today announced it will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2019-20 flu season, immediately following licens...
Read more -
IAS 2019: ViiV Healthcare showcasing innovation in HIV science
Data to be presented span the company’s diverse portfolio, challenging the current treatment paradigm and investigating new options to meet the evolving needs of people living w...
Read more -
GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
Niraparib demonstrates significant improvement in progression free survival for women regardless of their biomarker status
Read more -
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with the 2-drug regimen Dovato (dolutegravir plus lamivudine) in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Week 48 results from the TANGO study will be presented this month at 10th International AIDS Society Conference on HIV Science (IAS 2019).
Read more -
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice
The long-acting injectable regimen has been granted Priority Review status by the FDA, with a target approval date set for December 29, 2019
Read more -
GSK announces phase III start for its anti GM-CSF antibody, otilimab, in patients with rheumatoid arthritis (RA)
First phase III program in RA to include head-to-head comparisons with current treatments across all pivotal studies in a broad range of difficult-to-treat RA patients
Read more -
GSK joins forces with the University of California to advance genomic research and improve drug discovery
New ‘Laboratory for Genomics Research’ unites CRISPR pioneers with industry expertise to help unravel mysteries of the human genome
Read more -
Nucala (mepolizumab) gains FDA approval for two new self-administration options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinject...
Read more -
Nucala (mepolizumab) receives positive CHMP opinion for new self-administration options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion re...
Read more -
Save the Children Announces $1.5 Million Grant from GSK to Enhance Disaster Relief
Save the Children is pleased to announce that global healthcare company GSK will donate $1.5 million over three years to help enhance the global nonprofit’s ability to respond t...
Read more -
GSK announces approval of Shingrix in China for prevention of shingles in adults aged 50 and over
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster)...
Read more -
GSK changes sales representative incentive program
We are announcing changes to our incentive program for sales representatives in certain countries. These changes reflect the growing shift in GSK’s portfolio to innovative Speci...
Read more -
GSK’s strong science prominent at ATS 2019
GlaxoSmithKline plc (LSE/NYSE: GSK) will present more than 70 abstracts at the American Thoracic Society (ATS) International Conference 17-22 May, Dallas, US
Read more -
GSK Science in the Summer™ Aims to Inspire Youth with STEM Learning through the ‘Science of Me’
The popular free summer program, sponsored by global healthcare company GSK and operated by Philadelphia’s renowned science learning space, The Franklin Institute, kicks off reg...
Read more -
Phase III CAPTAIN study of Trelegy Ellipta in patients with asthma meets primary endpoint
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler trip...
Read more -
GSK delivers sales of £7.7 billion +6% AER, +5% CER
Total EPS 16.8p, +50% AER, +42% CER; Adjusted EPS 30.1p, +22% AER, +18% CER
Read more -
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
